1. Home
  2. VSTD vs TOVX Comparison

VSTD vs TOVX Comparison

Compare VSTD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSTD

Vestand Inc.

N/A

Current Price

$0.23

Market Cap

6.3M

ML Signal

N/A

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.19

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTD
TOVX
Founded
2016
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
7.3M
IPO Year
2022
2006

Fundamental Metrics

Financial Performance
Metric
VSTD
TOVX
Price
$0.23
$0.19
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
659.1K
3.0M
Earning Date
03-27-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,902,861.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.39
N/A
52 Week Low
$0.20
$0.17
52 Week High
$5.63
$2.03

Technical Indicators

Market Signals
Indicator
VSTD
TOVX
Relative Strength Index (RSI) N/A 40.40
Support Level N/A $0.17
Resistance Level N/A $0.23
Average True Range (ATR) 0.00 0.02
MACD 0.00 0.00
Stochastic Oscillator 0.00 32.34

Price Performance

Historical Comparison
VSTD
TOVX

About VSTD Vestand Inc.

Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: